Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 15/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.73 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.73 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.73 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.56 |
| ▸ | TNKS | O95271 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317442 | 0.88 | PARP10 (0.77) | PARP10PARP3PARP15ALDH1A1PARP14 | |
| SCHEMBL8546200 | 0.87 | PARP10 (0.77) | PARP10PARP3PARP15ALDH1A1PARP14 | |
| SCHEMBL3137816 | 0.85 | PARP10 (1.00) | PARP10PARP3PARP15ALDH1A1PARP14 | |
| SCHEMBL28313588 | 0.83 | PARP10 (0.73) | PARP10PARP3PARP15ALDH1A1PARP14 | |
| SCHEMBL1448984 | 0.82 | ALDH1A1 (0.76) | PARP10PARP3PARP15ALDH1A1PARP14 | |
| SCHEMBL19048679 | 0.82 | PARP10 (0.69) | PARP10PARP3PARP15ALDH1A1PARP14 | |
| SCHEMBL1663469 | 0.81 | PARP10 (0.65) | PARP10PARP3ALDH1A1KMT2AKDM4E | |
| SCHEMBL5050902 | 0.81 | PARP10 (0.65) | PARP10PARP3ALDH1A1KMT2AKDM4E | |
| SCHEMBL10397006 | 0.81 | HPGD (0.73) | PARP10PARP3PARP15ALDH1A1PARP14 | |
| SCHEMBL28636841 | 0.81 | PARP10 (0.68) | PARP10PARP3PARP15ALDH1A1PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544972-B1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3544972-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | Pfizer Inc (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| CN-110234638-A | Heteroaryl phenoxy benzamide KAPPA opiates ligand | 辉瑞大药厂 | 2019-09-13 | — | — | CN | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018096510-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1562595-B1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | disclosed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | PARP10 1704/4885PARP3 2239/4885PARP15 1456/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | PARP10 2434/4885PARP3 4263/4885PARP15 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.